News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
707,830 Results
Type
Article (40769)
Company Profile (289)
Press Release (666772)
Multimedia
Podcasts (48)
Webinars (12)
Section
Business (206903)
Career Advice (2046)
Deals (35739)
Drug Delivery (98)
Drug Development (81914)
Employer Resources (174)
FDA (16220)
Job Trends (15033)
News (349272)
Policy (32819)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (7)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (7)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (8)
2024 Pharm Country Standard (4)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2583)
Accelerated approval (5)
Adcomms (20)
Allergies (83)
Alliances (50309)
ALS (90)
Alzheimer's disease (1380)
Antibody-drug conjugate (ADC) (114)
Approvals (16223)
Artificial intelligence (247)
Autoimmune disease (20)
Automation (15)
Bankruptcy (363)
Best Places to Work (11708)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (213)
Bladder cancer (60)
Brain cancer (26)
Breast cancer (263)
Cancer (2102)
Cardiovascular disease (167)
Career advice (1709)
Career pathing (29)
CAR-T (146)
Cell therapy (413)
Cervical cancer (19)
Clinical research (66512)
Collaboration (811)
Compensation (509)
Complete response letters (19)
COVID-19 (2610)
CRISPR (39)
C-suite (229)
Cystic fibrosis (100)
Data (2067)
Decentralized trials (2)
Denatured (17)
Depression (41)
Diabetes (257)
Diagnostics (6386)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (119)
Drug pricing (96)
Drug shortages (25)
Duchenne muscular dystrophy (91)
Earnings (86858)
Editorial (37)
Employer branding (21)
Employer resources (148)
Events (114785)
Executive appointments (705)
FDA (17414)
Featured Employer (48)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (732)
Gene editing (102)
Generative AI (21)
Gene therapy (295)
GLP-1 (704)
Government (4430)
Grass and pollen (4)
Guidances (51)
Healthcare (18911)
Huntington's disease (23)
IgA nephropathy (24)
Immunology and inflammation (109)
Indications (27)
Infectious disease (2751)
Inflammatory bowel disease (134)
Inflation Reduction Act (8)
Influenza (50)
Intellectual property (93)
Interviews (315)
IPO (16612)
IRA (40)
Job creations (3744)
Job search strategy (1455)
Kidney cancer (9)
Labor market (36)
Layoffs (463)
Leadership (16)
Legal (7983)
Liver cancer (72)
Lung cancer (303)
Lymphoma (140)
Machine learning (5)
Management (58)
Manufacturing (290)
MASH (62)
Medical device (13371)
Medtech (13376)
Mergers & acquisitions (19641)
Metabolic disorders (662)
Multiple sclerosis (76)
NASH (16)
Neurodegenerative disease (86)
Neuropsychiatric disorders (24)
Neuroscience (1893)
NextGen: Class of 2025 (6584)
Non-profit (4505)
Northern California (2560)
Now hiring (38)
Obesity (357)
Opinion (215)
Ovarian cancer (73)
Pain (80)
Pancreatic cancer (81)
Parkinson's disease (147)
Partnered (21)
Patents (225)
Patient recruitment (100)
Peanut (47)
People (58265)
Pharmaceutical (68)
Pharmacy benefit managers (18)
Phase I (20796)
Phase II (29333)
Phase III (21709)
Pipeline (1119)
Policy (132)
Postmarket research (2572)
Preclinical (8814)
Press Release (71)
Prostate cancer (98)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (376)
Real estate (6071)
Recruiting (67)
Regulatory (22403)
Reports (46)
Research institute (2352)
Resumes & cover letters (354)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (66)
Series A (125)
Series B (85)
Service/supplier (11)
Sickle cell disease (54)
Southern California (2201)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (28)
Startups (3681)
State (2)
Stomach cancer (13)
Supply chain (65)
Tariffs (24)
The Weekly (29)
United States (22285)
Vaccines (672)
Venture capitalists (39)
Weight loss (234)
Women's health (34)
Worklife (15)
Date
Last 7 days (476)
Last 30 days (2222)
Last 365 days (33221)
2025 (9332)
2024 (35647)
2023 (40439)
2022 (51646)
2021 (56116)
2020 (54486)
2019 (46925)
2018 (35353)
2017 (32536)
2016 (32061)
2015 (38048)
2014 (31823)
2013 (26862)
2012 (29179)
2011 (29853)
2010 (27943)
Location
Africa (748)
Alabama (52)
Alaska (7)
Arizona (232)
Arkansas (13)
Asia (38734)
Australia (6462)
California (5844)
Canada (1943)
China (496)
Colorado (255)
Connecticut (268)
Delaware (136)
Europe (83706)
Florida (861)
Georgia (203)
Idaho (57)
Illinois (541)
India (25)
Indiana (302)
Iowa (9)
Japan (151)
Kansas (106)
Kentucky (23)
Louisiana (9)
Maine (62)
Maryland (863)
Massachusetts (4402)
Michigan (216)
Minnesota (379)
Mississippi (2)
Missouri (78)
Montana (30)
Nebraska (25)
Nevada (60)
New Hampshire (63)
New Jersey (1679)
New Mexico (29)
New York (1662)
North Carolina (962)
North Dakota (7)
Northern California (2560)
Ohio (195)
Oklahoma (14)
Oregon (33)
Pennsylvania (1318)
Puerto Rico (11)
Rhode Island (30)
South America (1137)
South Carolina (20)
South Dakota (1)
Southern California (2201)
Tennessee (100)
Texas (869)
Utah (174)
Virginia (138)
Washington D.C. (59)
Washington State (540)
West Virginia (3)
Wisconsin (52)
707,830 Results for "syngenta biotechnology inc sbi".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Transpara® Showcases Innovative FDA Cleared Breast AI Capabilities including Breast Density Assessment and Temporal Comparison to Elevate Radiologist Performance at SBI
April 16, 2025
·
3 min read
Business
Syngenta Group Reports H1 2023 Results
Syngenta Group announced financial results for the first half and the second quarter of 2023.
August 31, 2023
·
10 min read
Drug Development
Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion
Skye Bioscience, Inc. has treated the first patient in its Phase 2 clinical trial evaluating SBI-100 Ophthalmic Emulsion’s (“OE”) ability to lower intraocular pressure (“IOP”), safety and relevant biomarkers, in patients with primary open-angle glaucoma (“POAG”) or ocular hypertension (“OHT”).
November 28, 2023
·
6 min read
News
Syngenta collaborates with Ginkgo Bioworks to enable faster launch of innovative biologicals
July 16, 2024
·
7 min read
Press Releases
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
March 7, 2025
·
8 min read
Press Releases
CorMedix Inc. Added to Nasdaq Biotechnology Index
December 20, 2024
·
1 min read
Press Releases
Adnexus Biotechnologies Inc. Unveils AI-Driven Malaria Cure with Trapicolast
January 7, 2025
·
4 min read
Drug Development
Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma
Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing drugs targeting the endocannabinoid system, initially focused on the CB1 receptor to address glaucoma and metabolic conditions, is pleased to report successful results from its Phase 1 clinical trial assessing the safety and pharmacokinetics of SBI-100 Ophthalmic Emulsion (“OE”).
October 25, 2023
·
8 min read
Syngenta Group Moves Forward With Its IPO Plans
Syngenta Group has withdrawn its STAR Market IPO application and will immediately apply for a public listing on the main board at the Shanghai Stock Exchange.
May 18, 2023
·
3 min read
Deals
Nika Pharmaceuticals, Inc. (NKPH) Merges With Nika Biotechnology, Inc.
Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH) announces its merger with Nika BioTechnology, Inc., effective as of March 1, 2024.
March 20, 2024
·
2 min read
1 of 70,783
Next
